14.6% of the participants qualified for participation based on elevated filling pressures, 13.4% based on hospitalization for heart failure within 12 months in combination with ongoing diuretic treatment or echocardiographic abnormalities (or both), and 72.0% based on NT-proBNP levels plus echocardiographic abnormalities Median body weight and BMI of participants were 105.1 kg and 37.0kg/m 2 , respectively At baseline, patients had substantial degree of heart failure related symptoms, physical limitations, and poor exercise tolerance Outcomes Primary Outcome Co-primary endpoints for Semaglutide vs placebo from baseline to week 52: Change in KCCQ-CSS 16.6 points vs 8.7 points (estimated difference, 7.8 points
"When you're giving so much to others, it can be hard to give back to yourself," says Robin Seale, Hers Weight Loss Program customer
Book Now Prices Includes an IV chelation compound to remove unwanted heavy metals in the body (soft tissue, bone, and blood)
Always work in a clean environment, and use aseptic techniques
